VOYG earnings call summary

Prepared Highlights

• Q1 2026 net sales were $35 million, up modestly year-over-year (CFO).
• Q1 bookings totaled $45 million, up 232% year-over-year in Defense and Space Technologies segment (CFO).
• Book-to-bill ratio of 1.3 (CEO, CFO).
• Backlog reached a record $275 million, up 54% year-over-year (CEO).
• Backlog growth driven by Golden Dome architecture awards, next-generation interceptor work, and a Raytheon contract for standard missile interceptor technologies (CEO, CFO).
• Adjusted EBITDA loss of $33 million for Q1 (CFO).
• Adjusted EPS loss of $0.61 per share for Q1 (CFO).
• Cash and cash equivalents of $429 million; total liquidity of $641 million including $212 million in credit facilities (CFO).
• Starlab received $24 million in cash payments from NASA in Q1; inception-to-date milestone cash receipts total $207 million (CFO).
• Internally funded R&D (IRAD) was 17% of revenue in Q1; total innovation spend was 48%, excluding Starlab (CEO).
• Capital expenditures, excluding Starlab, expected to be approximately $60 million to $70 million for 2026 (CFO).
• Official guidance: 2026 revenue guidance raised to $230 million to $255 million, representing 38% to 53% year-over-year growth (CEO, CFO). Gross margin expected in mid-teens for the year (CFO). IRAD expected to increase to approximately 20% of sales (CFO).

Mgmt Quotes

• "Voyager had an outstanding first quarter with record backlog, a book-to-bill ratio of 1.3 and significant traction on new contracts, including Golden Dome." (CEO)
• "We are increasing our 2026 revenue guidance to $230 million to $255 million, a significant acceleration relative to last year." (CEO)
• "Our ability to deploy differentiated capabilities across complex architectures, whether as a prime or a key technology partner, strongly positions us to participate across multiple programs as they move from development into production." (CEO)
• "We are off to a fantastic start, executing well and progressing on all of our strategic initiatives." (CEO)
• "The first quarter reflected disciplined execution, strong bookings, expansion of backlog to a new record level. We are investing ahead of growth, and we're supported by improving demand and ample liquidity." (CFO)

Prepared Metrics

Q&A Batch (1-5 of 5)

Q1 — Sheila Kahyaoglu

• Topic: Backlog increase and Golden Dome program wins
• Key points:
  • Q1 backlog increased despite typical seasonal downward trend; key wins include being added to Raytheon's standard missile program and a new Anduril relationship on space-based interceptors (announced 15 minutes before call).
  • Guidance low end raised due to conversion of pipeline (>$5 billion) into backlog; midpoint/top end reserved for future quarters.
• Mgmt stance: Bullish — technology validation and accelerated program additions beyond IPO expectations.

Q2 — Alexander Christian Preston

• Topic: Anduril award details and Starlab/CLD outlook
• Key points:
  • Anduril award pertains to space-based interceptors (SBI) under Golden Dome; multiple Voyager technologies involved; additional SBI news forthcoming.
  • Starlab: 130% of commercial demand capacity spoken for; passed 4 milestones in Q1 with cash payments; won PAM7 Private Astronaut Mission from NASA (Q2 award, not yet in backlog).
• Mgmt stance: Bullish — technology central to Golden Dome architectures; well-positioned for any NASA CLD path.

Q3 — Myles Walton

• Topic: Standard missile contract context and revenue cadence
• Key points:
  • SM-3 contract is a preproduction award, incremental to prior pipeline; initial contract from Raytheon, with upside beyond 2026.
  • Q1 revenue $35M (slightly up YoY); headwinds from rolling off Space Doc 2 (~$5M) and Airbus software contract.
  • Q2 revenue expected to increase 37% sequentially to high $40M; full-year split: 33% H1, 67% H2; Q1 book-to-bill 1.3x, Q2 expected >1x with >$45M bookings.
• Mgmt stance: Bullish — strong backlog visibility and accelerating bookings momentum.

Q4 — Christopher Barbero

• Topic: Gross margin drivers and segment restructuring
• Key points:
  • Q1 gross margin negative due to program mix and incremental investment ahead of growth; full-year guidance mid-teens (14%-15%).
  • Q2 gross margin expected positive low-mid single digits; Q3 mid-to-high teens; Q4 mid-20s.
  • Defense and Space segments merged into one; internal integration already underway after 3 strategic acquisitions (EMSI, ExoTerra, Estes).
• Mgmt stance: Neutral — margin ramp tied to revenue acceleration; segment merger reflects operational convergence.

Q5 — John Godyn

• Topic: AI investments and revenue guidance flexibility
• Key points:
  • AI focus on reducing cycle time (e.g., custom ASIC design from multiyear to multimonth); senior-level sponsorship (President Matt Kuta, CTO Paul Tilghman, new hire from DARPA labs).
  • Revenue guidance low end raised; top end unchanged due to early year and customer schedule variability; 67% of full-year revenue in H2, substantial in Q4.
• Mgmt stance: Bullish on AI impact (early but significant); cautious on top-end guidance until Q2 visibility crystallized.

Q&A Batch (6-10 of 10)

Q6 — Anton (代 Gautam)

• Topic: Starlab 收入确认时间表及预收款指标
• Key points:
  • 最早可能在 2027 年开始确认地面培训相关收入，2028 年收入将更具实质意义。
  • 预计最早在 2026 年就能看到预收款（advanced bookings），并将在 2027 年及以后加速。
  • 管理层强调关注资产负债表的递延收入（deferred revenue）作为先行指标。
  • 目前已锁定超过 130% 的商业运力。
• Mgmt stance: 乐观。管理层认为预收款将在 2026 年开始转化为现金预订，这是最有力的财务指标，并将在 2027 至 2028 年转化为收入。

Q7 — Michael Leshock

• Topic: Golden Dome 项目早期收入的利润率属性
• Key points:
  • 管理层明确该合同为预生产合同（preproduction contract），而非研发（R&D）性质。
  • 该合同为固定总价合同（firm fixed price contract）。
  • 当前毛利率预期在 20% 以上，属于健康水平。
  • 随着进入更高产量的生产阶段，预计利润率将进一步提升。
• Mgmt stance: 乐观。管理层认为早期阶段即拥有超过 20% 的健康利润率，且未来进入量产阶段后利润率有改善和提升的空间。

Q8 — Kristine Liwag

• Topic: Starlab 独立融资的可行性及 CLD Phase 2 进展
• Key points:
  • 管理层确认，即使 NASA CLD 项目最终未能按预期落地，理论上存在独立融资推进 Starlab 的可能性，但认为这种情况不太可能发生。
  • 重申了涵盖低地球轨道（LEO）、月球（Lunar）和深空（Lagrangian）的“3L”战略，并提及月球栖息地计划及对 Max Space 的投资。
  • 关于 CLD Phase 2 的里程碑，分析师追问了项目是否仍在暂停状态以及是否预计在夏初公布中标结果，管理层未直接给出明确时间点。
  • 关于独立推进 Starlab 所需的具体资金规模，管理层表示取决于最终的设计和参数，未给出具体数字。
• Mgmt stance: 乐观。管理层认为公司极有可能赢得 CLD Phase 2，并对包含 Starlab 在内的整体太空经济战略前景非常看好。

Q9 — Kristine Liwag

• Topic: 与 Anduril 合作关系的排他性
• Key points:
  • 分析师询问与 Anduril 在太空基拦截器（SBI）方面的合作是否为独家。
  • 管理层回应称，公司参与了多个中标团队（multiple award-winning teams），暗示合作关系并非独家。
• Mgmt stance: 中性偏乐观。管理层通过强调参与多个团队，展示了公司在 SBI 领域的广泛布局，但未提供更多具体细节。

Q10 — Steven Wahrhaftig

• Topic: 国防预算扩张对 Voyager 的潜在影响
• Key points:
  • 分析师指出 2027 财年国防预算预期将扩大至约 1.5 万亿美元，其中包含约 750 亿美元的弹药采购和 170 亿美元专门用于 Golden Dome。
  • 分析师询问 Voyager 如何从这笔增量预算中获益，以及公司项目属于预算中的和解法案部分还是可自由支配基础部分。
  • 管理层回应称，1.5 万亿美元的国防预算对整个行业和 Voyager 都将是巨大顺风，但未及详细说明具体项目归属即被中断。
• Mgmt stance: 乐观。管理层认为如此规模的预算对行业和公司而言是绝对的利好。